Multi-specialty telehealth platform, Hims & Hers, has launched two new prescription offerings to provide women with more effective solutions to address hair loss.
The two solutions, Topical Finasteride & Minoxidil Spray and Oral Spironolactone, aim to address a condition roughly 30 million women in the U.S. alone experience at some time in their lives.
“This launch is the direct result of Hers’ close relationship with our consumers, listening to their health goals and what they feel is missing from the hair loss market,” said Hilary Coles, co-founder and SVP of brand and innovation at Hims & Hers. “Our ability to continue to bring clinically-proven ingredients to market in a unique dosage form through innovative compounding preparations remains unparalleled. We’ve made it our mission to destigmatize issues like hair loss so that women aren’t embarrassed to confidently take control of their health!”
The launch of the offering comes at a time when medical experts are seeing an increase in stress-related hair loss cases. According to Hims & Hers, hair loss-related internet searches have increased by 8 percent since February 2021. That is the equivalent of more than 829,000 queries a month in the U.S. alone.
The Topical Finasteride & Minoxidil Spray combines two clinically proven ingredients and includes exactly 3% finasteride and 6% minoxidil. Meanwhile, the Oral Spironolactone offering is a once-a-day antiandrogen pill that is clinically proven to slow down shedding and regrow new hair.
Shoppers looking to purchase either new prescription offerings will need to complete a consultation with a healthcare provider through the Hims & Hers platform.
More information can be found on the Hers website.